NorthStar Medical Radioisotopes, LLC is a nuclear medicine technology company committed to providing reliable U.S.-based and environmentally sustainable radioisotope supply solutions. The FDA-approved RadioGenix™ System is its first product for use in producing medically critical technetium-99m (Tc-99m) from non-uranium molybdenum-99 (Mo-99) target material. NorthStar's existing and future technology platforms are set to potentially provide additional solutions in diagnostic and therapeutic markets.